MGC Pharmaceuticals Ltd

Compliance Release - Application for Admission to Trading

13 February 2024

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ("MGC Pharma" or the "Company") is applying for admission to the Financial Conduct Authority's Official List and to trading on the Main Market of London Stock Exchange plc ("Admission") of 283,150 fully paid ordinary shares ("Shares") previously issued by MGC Pharma. Admission of the Shares is expected to take place at 8:00am (GMT) on 19 February 2024.

Details of the 283,150 Shares are as follows:

·      1,600 Shares issued upon the conversion of securities granted under the Company's Employee Share Scheme;

·      43,692 Shares issued to suppliers of the Company in lieu of cash settlement;

·      107,483 shares issued to employees under the Company's Employee Share Scheme; and

·      130,375 shares issued to investors pursuant to a capital raising that took place in 2023.

The Shares have already been issued and quoted on the ASX and application for Admission will not affect the Total Voting Rights in the Company. At the date of this announcement, the Company has 43,851,631 Shares in issue, each with one voting right. Therefore, the Company's total number of Shares in issue and voting rights will be 43,851,631 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

Authorised for release by the Managing Director, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma